Cardiex Ltd (CDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cardiex Ltd (CDX) has a cash flow conversion efficiency ratio of -0.452x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.99 Million ≈ $-2.11 Million USD) by net assets (AU$6.60 Million ≈ $4.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CDX equity to assets ratio to measure how much of total assets are equity-financed.
Cardiex Ltd - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Cardiex Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Cardiex Ltd (CDX) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Cardiex Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cardiex Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PT Jaya Bersama Indo Tbk
JK:DUCK
|
-0.035x |
|
Pasinex Resources Limited
F:PNX
|
-0.047x |
|
Purefun Group AB
ST:PURE
|
0.088x |
|
TCS Group Holdings Bhd
KLSE:0221
|
-0.056x |
|
Daesang Corp Preference Shares
KO:001685
|
0.058x |
|
Inbest Prime III Inmuebles SOCIMI S.A.
MC:YINB3
|
N/A |
|
Fourth-Link Inc.
KQ:056730
|
0.000x |
|
Oncosil Medical Ltd
AU:OSL
|
-1.814x |
Annual Cash Flow Conversion Efficiency for Cardiex Ltd (2005–2024)
The table below shows the annual cash flow conversion efficiency of Cardiex Ltd from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see Cardiex Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | AU$4.09 Million ≈ $2.89 Million |
AU$-7.72 Million ≈ $-5.46 Million |
-1.889x | -115.76% |
| 2023-06-30 | AU$-1.00 Million ≈ $-708.11K |
AU$-12.00 Million ≈ $-8.49 Million |
11.987x | +924.03% |
| 2022-06-30 | AU$6.61 Million ≈ $4.68 Million |
AU$-9.62 Million ≈ $-6.80 Million |
-1.455x | -189.65% |
| 2021-06-30 | AU$7.91 Million ≈ $5.60 Million |
AU$-3.97 Million ≈ $-2.81 Million |
-0.502x | -73.83% |
| 2020-06-30 | AU$5.88 Million ≈ $4.16 Million |
AU$-1.70 Million ≈ $-1.20 Million |
-0.289x | +12.33% |
| 2019-06-30 | AU$6.95 Million ≈ $4.92 Million |
AU$-2.29 Million ≈ $-1.62 Million |
-0.330x | -630.02% |
| 2018-06-30 | AU$4.60 Million ≈ $3.25 Million |
AU$-207.49K ≈ $-146.82K |
-0.045x | +98.04% |
| 2017-06-30 | AU$1.33 Million ≈ $939.99K |
AU$-3.07 Million ≈ $-2.17 Million |
-2.308x | -47.31% |
| 2016-06-30 | AU$3.14 Million ≈ $2.22 Million |
AU$-4.92 Million ≈ $-3.48 Million |
-1.567x | -245.40% |
| 2015-06-30 | AU$4.33 Million ≈ $3.07 Million |
AU$-1.97 Million ≈ $-1.39 Million |
-0.454x | -9.20% |
| 2014-06-30 | AU$3.28 Million ≈ $2.32 Million |
AU$-1.36 Million ≈ $-965.08K |
-0.415x | -214.06% |
| 2013-06-30 | AU$4.88 Million ≈ $3.45 Million |
AU$1.78 Million ≈ $1.26 Million |
0.364x | +158.04% |
| 2012-06-30 | AU$1.88 Million ≈ $1.33 Million |
AU$-1.18 Million ≈ $-836.57K |
-0.627x | -0.39% |
| 2011-06-30 | AU$3.03 Million ≈ $2.15 Million |
AU$-1.90 Million ≈ $-1.34 Million |
-0.625x | +9.43% |
| 2010-06-30 | AU$3.74 Million ≈ $2.64 Million |
AU$-2.58 Million ≈ $-1.82 Million |
-0.690x | -402.75% |
| 2009-06-30 | AU$4.65 Million ≈ $3.29 Million |
AU$-637.56K ≈ $-451.11K |
-0.137x | +78.34% |
| 2008-06-30 | AU$5.96 Million ≈ $4.22 Million |
AU$-3.78 Million ≈ $-2.67 Million |
-0.634x | -32.50% |
| 2007-06-30 | AU$9.38 Million ≈ $6.64 Million |
AU$-4.49 Million ≈ $-3.18 Million |
-0.478x | -61.50% |
| 2006-06-30 | AU$14.41 Million ≈ $10.19 Million |
AU$-4.27 Million ≈ $-3.02 Million |
-0.296x | -126.85% |
| 2005-06-30 | AU$18.80 Million ≈ $13.30 Million |
AU$-2.45 Million ≈ $-1.74 Million |
-0.131x | -- |
About Cardiex Ltd
Conneqt Health Limited engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific. It offers SphygmoCor, a vascular biometric technology that captures central hemodynamics and arterial stiffness for noninvasive measurement of vascular biomarkers including central aortic pressures and arterial stiffnes… Read more